This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

Bilateral Robot-assisted Upper Extremity Rehabilitation on Motor Recovery in People With Subacute Stroke

Sponsored by IRCCS San Raffaele Roma

About this trial

Last updated a year ago

Study ID

93/SR/24

Status

Recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18+ Years
All Sexes

Trial Timing

Started 2 years ago

What is this trial about?

The goal of this clinical trial is to study the clinical effects of a robotic rehabilitation treatment through a bilateral exoskeleton (Bilateral Robot-Assisted Therapy-BRAT) during standard rehabilitation, on motor recovery, compared to conventional arm re-education in people suffering from stroke in the subacute phase. The main question it aims to answer is what the effectiveness of Bilateral Robot-Assisted Therapy (BRAT) is in rehabilitating the upper limb in individuals with subacute stroke compared to conventional rehabilitation treatment in terms of motor function improvement as measured by the Fugl-Meyer Assessment - Upper Limb (FMA-UL), motor domain. Researchers will compare two groups (Experimental Group - EG and Control Group - CG) to see if the BRAT is more effective than conventional rehabilitation treatment in terms of motor recovery. Participants will be randomly assigned to one of the two treatment groups (EG or CG) and will be clinically and instrumentally evaluated at baseline (T0) and at the end of treatment (T1). EG, in addition to the standard rehabilitation treatment, will perform a 45-minute session of BRAT per day through the Arm Light Exoskeleton Hybrid (Alex RS - Wearable Robotics) robotic system. The CG, in addition to the standard routine rehabilitation treatment, will follow a conventional rehabilitation of the upper limbs without the use of technological devices. Finally, a telephone follow-up is scheduled three months after the end of the treatment.

What are the participation requirements?

Inclusion Criteria

* Both sexes;

* Age >18 years;

* Unilateral hemipyramidal syndrome as demonstrated by a brain CT or MRI;

* Distance from acute event < 6 months;

* Modified Ashworth Scale (MAS) of shoulder, elbow, and wrist <3;

* Ability to understand and sign the informed consent for the study;

* Ability to perform the study procedures.

Exclusion Criteria

* Unstable general clinical conditions;

* Bilateral pyramidal hemisyndrome severe visual impairment;

* Recent injection of Botulinum Toxin to the affected upper limb or planned for the duration of the study;

* Interruption of treatment for 1 week or 5 consecutive sessions;

* Inability to adhere to the exercise program due to poor compliance;

* Presence of neurological pathologies superimposed on the stroke event, psychiatric complications or personality disorders;

* Presence of osteoarticular and neuromuscular pathologies that may compromise the motor skills of the upper limb;

* Participants who have not signed the informed consent to the study.